Multiple Myeloma Day

Posted on Mar 29, 2019 by Delveinsight

Multiple Myeloma Day

Multiple Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers. For more information on Multiple Myeloma, click here-https://bit.ly/2HKs5da

(Visited 135 times, 1 visits today)

←

Previous Story
The Business Cocktail

→

Next Story
Global Traveler’s Diarrhea Market

Pfizer’s Somatrogon; SCONE device; ATG-010; SanBio in Neurology

Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results

Jan 5, 2021• Pharma, Latest Pharma News, Health News

Pfizer and OPKO Health: A step closer to FDA Nod for pediatric growth hormone deficiency (GHD) drug, Somatrogon Pfizer and Opko had joined...

Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse

Sep 7, 2020• Articles

The Multiple Myeloma Market is expected to grow during the study period 2017-30 due to a rich and robust pipeline, increasing incidence,...

Notizia

Jun 4, 2019• Business Consultant, DelveInsight's Drug Report, DelveInsight's Oncology based Reports, Notizia - Recent Pharma, Healthcare and Biotech Happenings, Pharma Consultant

Sanofi’s Isatuximab combo extends lives in multiple myeloma Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody,...

Multiple Myeloma Day

Related Posts

Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results

Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse

Notizia

Leave a Reply Cancel reply

Popular Posts

Recent Posts

Categories

Trending Posts

Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M

Which Pharma Companies are Working to Mitigate the Burden of Digestive Disorders?

Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy

Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space

Ewing Sarcoma: Key Companies and Emerging Therapies in the Landscape

Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

Sleep Disorders: An Emerging Public Health Issue

Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities

Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market

Limited Therapeutics Options and A Weak Pipeline: What Lies Ahead in the Cancer Anorexia Market?

Sections